Edition:
United States

Heron Therapeutics Inc (HRTX.OQ)

HRTX.OQ on NASDAQ Stock Exchange Capital Market

16.30USD
20 Nov 2017
Change (% chg)

$0.35 (+2.19%)
Prev Close
$15.95
Open
$16.00
Day's High
$16.35
Day's Low
$15.80
Volume
103,153
Avg. Vol
150,963
52-wk High
$19.15
52-wk Low
$12.25

Chart for

About

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery... (more)

Overall

Beta: 2.07
Market Cap(Mil.): $869.35
Shares Outstanding(Mil.): 54.50
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BUZZ-Heron Therapeutics: FDA approves chemotherapy-induced nausea drug

** Drug developer's shares rise 4.9 pct to $18.20 after market

Nov 09 2017

BRIEF-Heron Therapeutics gets FDA approval for Cinvanti

* Announces U.S. FDA approval of Cinvanti™ (aprepitant) injectable emulsion for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (cinv)

Nov 09 2017

BRIEF-Heron Therapeutics reports qtrly diluted net loss per share $0.77

* Heron Therapeutics reports financial results for the three and nine months ended September 30, 2017 and recent corporate progress

Nov 06 2017

BRIEF-Heron Therapeutics granted FDA fast track designation for HTX-011

* Heron Therapeutics granted FDA fast track designation for HTX-011 to reduce postoperative pain and the need for opioid analgesics for 72 hours

Oct 26 2017

BRIEF-Heron Therapeutics initiates phase 3 program for HTX-011

* Heron Therapeutics announces initiation of phase 3 program for HTX-011 in postoperative pain following successful end-of-phase 2 meeting with FDA

Aug 09 2017

BRIEF-Heron Therapeutics reports quarterly loss per share $0.80

* Heron Therapeutics reports financial results for the three and six months ended June 30, 2017 and recent corporate progress

Aug 09 2017

Competitors

Earnings vs. Estimates